dsm-firmenich Pharma Solutions

Therapeutic breakthroughs in the cannabinoid space necessitate robust research – and this requires high-quality cannabinoid research material. That’s where dsm-firmenich’s new sampling program comes in. It offers the scientific community a unique opportunity to apply for samples of trial-ready, quality-tested cannabidiol GMP API isolate and a first-of-its-kind formulated cannabidiol drug intermediate, CBtru®. In our latest blog, we talked to Innovation Project Manager and program lead, Zdravka Misic, about how the program will help to safeguard cannabidiol-based research. Zdravka comments: “Within the cannabinoid space, the scientific community seeks a gold standard in material quality to increase the odds of research success. Through our sampling program, we’re excited to partner with likeminded researchers around the world to unlock the full therapeutic potential of cannabinoids and take steps towards better patient health.” 👉 Read the full blog here to learn more: https://bit.ly/46Xtju7 #cannabinoids #cannabinoidresearch #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth

The taste of medicines is a major factor influencing patient compliance. However, more than 60% of APIs on the market are considered to be bitter. Raising the question: How can drug formulators overcome bitterness to create more patient-friendly dosage forms? In our American Association of Pharmaceutical Scientists (AAPS) | aapscomms eCHALK TALK session, our taste experts – Guy Servant and Lyzandra Passarella-Dutour – share their expertise on this topic. Uncover: 💊The importance of taste in the formulation of new drug products 🔬The science behind taste and how flavors can be used to modulate taste perception 🧪Insights on dsm-firmenich’s novel bitter blockers 📑The safety and regulatory processes for developing and using innovative taste modulators Watch the session on-demand: https://bit.ly/3LRegIA #excipients #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth

At dsm-firmenich, we believe that powerful collaborations are the key to elevating research and development. This includes the field of cannabinoid-based early drug development. Together with Oz Medicann Group pharma – OMG pharma – we pioneer the development of a first-to-market #cannabidiol orally disintegrating tablet (ODT) for insomnia management with: 1️⃣ Optimized bioavailability 2️⃣ Higher active drug loading 3️⃣ Improved pharmacokinetic performance Beyond #insomnia, our joint expertise is also set to address the unmet need for more patient-friendly cannabinoid-based oral solid dosage forms for numerous conditions. Download our case study for the full story: https://bit.ly/3LqNsPc #cannabinoids #APIs #pharmaceuticals #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth

How do APIs with off-tastes interact with taste receptors?  Learn from dsm-firmenich experts, Guy Servant, Ph.D, Head of Taste Receptor-Based Discovery, and Lyzandra Passarella-Dutour, M. Sc., Global Taste Technical Director how drug developers can modulate taste receptor activities to enable the ultimate flavor perception. From diving into the important regulatory requirements for using flavoring agents in drugs to helping manufacturers unlock the full potential of innovative medicines.  👉 Watch our latest American Association of Pharmaceutical Scientists (AAPS) | @aapscomms eCHALK TALK session to get the latest insights on optimizing taste to elevate pharmaceutical formulations: https://bit.ly/3Wvi9YK #excipients #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth

In collaboration with Oz Medicann Group pharma – OMG pharma – an Australian-based biotech innovator in the #cannabinoid medicines domain, we’re inspiring a new era in cannabinoid-based drug delivery. Our mission? To develop formulations with enhanced bioavailability, palatability and patient convenience. In an interview, John Leith, CEO of OMG pharma, highlighted the value of our collaboration and opportunities it will unlock in the cannabinoid space. He emphasized that reliable access to scientific expertise and global regulatory support is instrumental in the development of novel cannabinoid-based formulations. Discover how dsm-firmenich and OMG pharma are set to develop a more patient-centric cannabidiol oral dosage form in our new case study: https://bit.ly/4bNhGXm #cannabinoids #cannabidiol #APIs #pharmaceuticals #drugdevelopment #dsmfirmenichPharma

To unlock the full potential of cannabinoid-based medicines, the pharmaceutical industry must first address the challenges of bioavailability and patient-centricity associated with current oil-based solutions. That’s why we set ourselves a challenge to develop an innovative, fast-acting and patient-friendly #cannabidiol formulation. In collaboration with Oz Medicann Group pharma – OMG pharma – we use our CBtru® drug product intermediate to enable the development of a first-to-market orally disintegrating tablet (ODT) with higher drug loading and optimized bioavailability, helping to elevate patient convenience and compliance. Want to know the full story? Download the case study: https://bit.ly/3WaFzSX #cannabinoids #APIs #pharmaceuticals #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth

We recently caught up with Oz Medicann Group pharma – OMG pharma – our partner and Australian-based biotech innovator in the #cannabinoid medicines domain, to discuss what our collaboration means for the future of patient treatment. Together, we’re exploring the therapeutic potential of cannabinoid-based orally disintegrating tablets (ODTs) for insomnia, a first-of-its-kind in the market. When asked about the benefits of novel ODT formats, John Leith, CEO at OMG pharma, revealed that they could be a more appealing and convenient drug delivery format compared to oil-based formulations. This makes ODTs a potential gamechanger in the cannabinoid realm. Download our case study to explore how we’re elevating patient care with OMG pharma: https://bit.ly/3WbGnai #cannabinoids #cannabidiol #APIs #pharmaceuticals #drugdevelopment #dsmfirmenichPharma

🔬 Interested in #cannabinoid-based research and development but concerns about risks holding you back? dsm-firmenich technical specialists, Zdravka Misic and Christiane Schweiggert, recently shared their key considerations for scientific success in this growing field of research during an eCHALK TALK session hosted by AAPS. Watch the session on-demand now to discover their insights and strategies for overcoming cannabinoid-based early drug development challenges. 👉🏻Watch now: https://lnkd.in/e3ASx3bv #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth

🔬 The pharmaceutical industry is rapidly evolving, driven by key trends, including: • Raising the bar on #sustainability • Securing supply chain resilience • Innovative delivery formats • Emerging therapeutic categories like #cannabinoids We can help drug developers leverage these trends to thrive in the pharmaceutical market. From our technical expertise to global regulatory perspective and high-quality ingredients, we’re uniquely positioned to support our customers’ drug development process. Dive into our new blog to learn more: https://bit.ly/3W6Lg5I #pharmatrends #supplychain #APIs #excipients

Have you ever wondered how to decrease the risk of failure and increase the odds of scientific success in cannabinoid-based research and development? Our technical experts, Zdravka Misic and Christiane Schweiggert, have shared their insights on this important question in a new webinar, including recommendations and strategies to support researchers and academics in this space. 👉🏻 Watch the on-demand session to learn how to navigate the complexities of #cannabinoid-based research and pave the way for groundbreaking discoveries: https://bit.ly/4daybOH #drugdevelopment #dsmfirmenichPharma #webringprogresstolife #togetherelevatinghealth